Bibliographic Details
| Title: |
Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial |
| Authors: |
Gladish, Deborah, Myers, Karen, Kuramochi, Yuki, Sewell, Christina, Balog, Craig, Kosty Sweeny, Denise, Kandrac, Jill, Spencer, Stephanie, Goyanes, Alice, Sahoo, Debasis, Dugar, Siddharth, Aguillon Prada, Robier, Nichols, Dave, Celiberti, Jeannie, Partisano, Annie, Fang, Fang, Coehlo, Jennifer, Perrin, Randy, Mandell, Brian, Gordon, Steven, Wiedemann, Herbert, Young, James, Greer, Joan, Ho, Ai-Chen, Ladd, Any, Mihalick, Virginia, Montpetit, Alison, O'Brine, Joyce, Owen, Catherine, Pal, Mary, Priday, Anna, Raj Sedhai, Yub, Wohlford, George, Hummel, Nicole, Korbee, Leslie, Cremer, Paul C *, Abbate, Antonio, Hudock, Kristin, McWilliams, Carla, Mehta, Jinesh, Chang, Steven Y, Sheng, Calvin C, Van Tassell, Benjamin, Bonaventura, Aldo, Vecchié, Alessandra, Carey, Brenna, Wang, Qiuqing, Wolski, Katherine E, Rajendram, Prabalini, Duggal, Abhijit, Wang, Tisha S, Paolini, John F, Trapnell, Bruce C |
| Source: |
In The Lancet Rheumatology June 2021 3(6):e410-e418 |
| Database: |
ScienceDirect |
